Study S000137

Effects of NNC0194-0499 Alone and in Combination With Semaglutide, of Semaglutide Alone, and of Cagrilintide Alone and in Combination With Semaglutide on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease

ClinicalTrials.gov record

Registration

Registration: NCT06409130
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 270
Start: 2024-05-20
Primary completion: 2025-11-21
Lead sponsor: Novo Nordisk A/S
Conditions: Alcohol-related Liver Disease
Interventions: DRUG:NNC0194-0499; DRUG:Semaglutide; DRUG:NNC0194-0499 placebo; DRUG:Semaglutide placebo (Group A); DRUG:Cagrilintide + semaglutide; DRUG:Cagrilintide; DRUG:Cagrilintide placebo; DRUG:Semaglutide placebo (Group B)
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1295-6713; OTHER:2023-508170-28; NIH:2023

Registered primary outcomes

Change in Enhanced Liver Fibrosis (ELF) [From week 0 to week 28]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.